BioSpace News Archive

RadNet, Inc. announced that it will host a conference call to discuss its second quarter 2022 financial results on Tuesday, August 9th, 2022 at 7:30 a.m. Pacific Time.

BIOLASE, Inc., the global leader in dental lasers, announced that the company has received five new United States patents and seven new foreign patents in the last 12 months.

Ginkgo to acquire Bayer’s 175,000-square-foot Biologics R&D center and enter into a new multi-year platform collaboration with Bayer to advance several agricultural biological programs.

Acquisition is expected to accelerate the development of Ginkgo’s innovative horizontal synthetic biology platform Expect integration of Zymergen’s complementary automation, software, and data science tools.

ENHERTU ® (fam-trastuzumab deruxtecan-nxki) granted Priority Review in the US for patients with HER2-low metastatic breast cancer.

Cytovale ® , a medical diagnostics company focused on providing rapid and insightful tools to improve early detection of fast-moving and immune-mediated diseases, will reveal its 510(k) pending Cytovale system and 10-minute IntelliSep ® sepsis risk stratification test at the American Association for Clinical Chemistry (AACC) annual meeting.

BridgeBio Pharma, Inc. (Nasdaq: BBIO) (BridgeBio), and Sentynl Therapeutics, Inc. (Sentynl), today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended that the European Commission authorize marketing under exceptional circumstances for NULIBRY.

Philogen S.p.A., a clinical-stage biotechnology company focused on antibody and small molecule-based targeted therapeutics, is pleased to announce the enrolment of 214 patients, in line with the protocol of its Phase III European trial of Nidlegy™ in locally advanced melanoma.

As the nation’s premier authority in cardiometabolic medicine, CMHC’s events are curated by the field’s leading experts to deliver the latest evidence-based interventions to improve health outcomes and quality of life for the growing number of patients at increased cardiometabolic risk.

AmMax Bio, Inc. (“AmMax”), a private clinical-stage biopharmaceutical company developing innovative therapeutics in oncology, including the development of the colony-stimulating factor 1 receptor (CSF1R) for tenosynovial giant cell tumor (TGCT), today announced that it has appointed Dorothy Nguyen, M.D., as Vice President of Clinical Development.